On July 22, 2009 REGiMMUNE Corporation reported that Astellas Pharma Inc. and REGiMMUNE have entered into a collaboration agreement to jointly research and develop a novel vaccine-platform technology (Press release, REGimmune, JUL 22, 2009, View Source [SID1234642238]). The partnership will combine Astellas’ broad range of capabilities in screening and developing natural source-derived compounds with REGiMMUNE’s immune liposome technology. Terms of the agreement have not been disclosed.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Our goal is to develop a potent vaccine-platform technology that enables effective vaccination with novel adjuvant and immune liposome technologies, increasing the efficiency of delivery to immune cells. Our approach will eliminate many of the current limitations for vaccine development," explained Haru Morita, CEO of REGiMMUNE. "This is particularly important for responding to new or changing virus strains. Astellas has a strong presence in immunology and is one of the largest vaccine distributors in Japan," Mr. Morita continued. "We believe this collaboration can produce a technology that will allow a rapid response to various viral outbreaks spreading around the world."
"We are pleased to initiate our first partnership with REGiMMUNE," stated Masafumi Nogimori, President and Chief Executive Officer of Astellas. "Disease prevention through timely and adequate vaccination is a key to maintaining human health. Astellas is committed to developing a new vaccine platform and this collaboration with REGiMMUNE will strengthen our position in this important area of disease prevention."
About Vaccines
Prophylactic vaccines need to elicit sufficient immune responses to protect individuals from the challenge by infectious agents. Most commonly, attenuated live viral particles are used to develop effective vaccines; however, development of live viral particles requires significant lead time and lengthy, costly manufacturing processes. While efforts have been made to develop improved adjuvants to enhance the potency of non-viral vaccines, Alum remains the only adjuvant approved by the U.S. FDA for use in humans. The Astellas-REGiMMUNE collaboration is expected to address these obstacles and provide a number of benefits over currently marketed products.